Agustin Andrade
Miami Beach, FLNPI 1104869064
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (59.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Cambridge Interventional LLC accounts for 64.4% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $9,150, 2.9 times the $3,153 reported in 2019.
Across 421 payments — averaging $71.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cambridge Interventional LLC$19K
- AbbVie$4K
- Sanofi-aventis U.S. LLC$1K
- Lilly USA, LLC$883
- Novo Nordisk$827
- AstraZeneca$633
- plus $4K from 26 others
What the payments were for
- Speaking & faculty fees$4,31314%
- Food & beverage$7,71426%
- Education$260%
- Other$18,00060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cambridge Interventional LLC | 6 | $19,356 |
| AbbVie | 44 | $3,687 |
| Sanofi-aventis U.S. LLC | 50 | $1,015 |
| Lilly USA, LLC | 47 | $883 |
| Novo Nordisk | 45 | $827 |
| AstraZeneca | 37 | $633 |
| IBSA Pharma Inc. | 28 | $440 |
| Currax Pharmaceuticals LLC | 25 | $388 |
| Amneal Pharmaceuticals LLC | 18 | $356 |
| Amgen(2 entities) | 16 | $314 |
| Regeneron Healthcare Solutions, Inc. | 10 | $222 |
| Mannkind Corporation | 18 | $207 |
| Shire North American Group Inc | 4 | $181 |
| Radius Health, Inc. | 9 | $178 |
| Insulet Corporation | 9 | $178 |
| Boehringer Ingelheim | 8 | $169 |
| Recordati_rare_diseases_inc. | 6 | $163 |
| Merck | 7 | $114 |
| Nalpropion Pharmaceuticals LLC | 6 | $107 |
| Corcept Therapeutics | 5 | $101 |
| Exelixis Inc. | 1 | $87 |
| Johnson & Johnson | 4 | $66 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 3 | $59 |
| Senseonics, Incorporated | 2 | $45 |
| Aegerion Pharmaceuticals, Inc. | 2 | $43 |
| Valeritas, Inc. | 2 | $42 |
| Amryt Pharma Holdings Ltd | 2 | $40 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| Pfizer | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 13 | $570,439 |
| IsturisaOsilodrostat Phosphate | 17 | $562,285 |
| MounjaroTirzepatide | 47 | $73,752 |
| JardianceEmpagliflozin | 47 | $54,133 |
| TymlosAbaloparatide | 11 | $28,538 |
| JanuviaSitagliptin Phosphate | 18 | $23,023 |
| SynthroidLevothyroxine Sodium | 221 | $21,949 |
| OzempicSemaglutide | 15 | $20,176 |
| TrulicityDulaglutide | 11 | $12,788 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $9,830 |
| LivaloPitavastatin Calcium | 11 | $6,852 |
| Cinacalcet Hcl | 23 | $4,727 |
| Levothyroxine Sodium | 329 | $3,417 |
| Calcitriol | 79 | $1,738 |
| Ezetimibe | 49 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $101 | $570,43913 claims |
| Recordati_rare_diseases_inc.Isturisa | $163 | $562,28517 claims |
| Lilly USA, LLCMounjaro, Trulicity | $883 | $86,54058 claims |
| Boehringer IngelheimJardiance | $169 | $54,13347 claims |
| Radius Health, Inc.Tymlos | $178 | $28,53811 claims |
| MerckJanuvia | $114 | $23,02318 claims |
| AbbVieSynthroid | $3,687 | $21,949221 claims |
| Novo NordiskOzempic | $827 | $20,17615 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $59 | $6,85211 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $356 | $3,508347 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Floridaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.